Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Harold Edward Fleming was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Summary

• Director Harold Edward Fleming received a grant of 13,000 stock options for CRISPR Therapeutics AG common shares.
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are set to expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• The value of the options is dependent on the future market performance of CRSP common shares.

Future Outlook

The options vest in 12 equal monthly installments, with the final installment vesting on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level scientific and industry expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-to-large cap biotech firms.
• The use of monthly vesting over one year is a standard retention mechanism for board members.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Director Compensation, Stock Options, Insider Transaction, Biotech